This mechanism is consistent with analyses of melanoma tissue after treatment with either anti-PD-(L)1 monotherapy, anti-CTLA-4 monotherapy, or in combination, which show distinct gene expression profiles associated with each type of treatment (22). Here, CTLA4 is linked to melanoma.